Cytogen's OncoRad
Executive Summary
Monoclonal antibody-linked yttrium-90 product is the firm's first therapeutic to reach human clinical testing. Phase I studies, to take place in Houston, will enroll patients with ovarian cancers that have proved resistant to current therapeutic regimens.